ARCHIVES

Study of Dlurectic Use As Renal Cell Cancer Risk Gets Concept Approval

This article is from The Cancer Letter archive.

Vol. 15 No. 11 | March 10, 1989

Download PDF Visit The Full Archive

Related Articles

FDA Approves Gleevec For First Line Rx Of CML

January 31, 2003

NCS Heeds Bloch’s Plea, To Consider Establishing Separate PDQ-Like System For General Public Use

December 7, 1984

ASCO Backs Sentinel Node Biopsy In Some Early Stage Breast Cancer

September 30, 2005

NCI Spent $381.2 Million On PR From 2006 to 2012, Vastly Outspending Other NIH, FDA Units

March 1, 2013

In Brief: Congress Sets NCI Rescission At $10.785 Million; Centers to Be Funded According To Priority Scores

June 12, 1981

UT System Launches Probe of Submission Of Controversial MD Anderson Grant

June 8, 2012